

# INNOVATIVE TREATMENTS HELPING PATIENTS WITH DISEASES IN THE CNS

Exciting portfolio of differentiated first-generation disease modifying agents in Alzheimer's and Parkinson's disease, diagnostics and pioneering complete spinal cord injury treatment

## SALSS CONTACT

**Gunilla Osswald**  
President & CEO

[gunilla.osswald@bioarctic.se](mailto:gunilla.osswald@bioarctic.se)  
+46 8 695 69 30

**BioArctic AB**  
Warfvinges väg 35  
SE-112 51 Stockholm  
Sweden

[www.bioarctic.se](http://www.bioarctic.se)

SALSS PRESENTING COMPANY | 2018



BioArctic AB | Nasdaq Stockholm: BIOA B

BioArctic AB is a clinical-stage biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and complete spinal cord injury. Founded in 2003, BioArctic is based around clinical discoveries that demonstrated the involvement of soluble aggregated forms of amyloid-beta (A $\beta$ ) protofibrils in disease pathogenesis.

## OUR PRODUCTS & SERVICES

BioArctic's lead clinical programme in AD is partnered with Eisai, targeting protein misfolding as a common causal pathway in neurodegeneration. BAN2401 (and a backup) are anti-A $\beta$  antibodies, selective for the soluble protofibrils, to eliminate neurotoxic A $\beta$  species. 18-mo analyses of BAN2401 Phase 2b clinical study, announced in July 2018, with 856 early AD patients, have demonstrated clinically meaningful and dose-dependent slowing in clinical decline and reduced A $\beta$  accumulation in the brain.

This is the first late-stage study successfully demonstrating potential disease-modifying effects on both cognition and biomarkers.

In PD, BioArctic collaborates with AbbVie on the anti-alpha-synuclein antibody BAN0805, which has shown powerful disease-modifying effects in pre-clinical studies.

SCO806 is a unique biodegradable device with FGF1, for the regenerative treatment of Complete SCI. Rat experiments demonstrate nerve regeneration, restored electrophysiology and motor function.

## WHAT MAKES US UNIQUE

The company has cutting-edge scientific competence, experience in developing drugs from idea to market and a solid cash position with more than SEK 1 billion. Collaborations with universities are of great importance to the company together with the strategically important global partners in the Alzheimer and Parkinson projects. BioArctic conducts its own clinical development in the field of complete spinal cord injury.

Through long-term collaboration agreements with global pharmaceutical companies, BioArctic has demonstrated high skill level and great ability to deliver innovative pharmaceutical projects.

## WHY YOU SHOULD MEET US

The project portfolio consists of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. We are interested to meet investors and potential licensing partners for our innovative programmes.

## KEY TEAM

**Gunilla Osswald, PhD**

- President & CEO
- 30+ years experience in drug development
- Formerly VP, Neurodegeneration Disease Modification, Astra Zeneca

**Lars Lannfelt, MD, PhD**

- Founder, Senior Vice President
- Senior Professor at Uppsala University
- Member of the Royal Swedish Academy of Sciences

**Hans Basun, MD**

- VP Clinical Development & CMO
- 20+ years pharma industry experience in leading positions in clinical research at Astra Arcus /AstraZeneca

**Christer Möller, PhD**

- VP Pre-clinical Development & CSO
- 20+ years drug development and clinical trial experience, including at Zymenex A/S

SWEDISH  
AMERICAN  
LIFE SCIENCE  
SUMMIT  
2018